Toxic optic neuropathy
diseaseOn this page
Summary
Toxic optic neuropathy (MONDO:0001688) is a disease and 3 clinical trials. Top therapeutic interventions include methylprednisolone hemisuccinate. A subtype of optic neuritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | toxic optic neuropathy |
| Mondo ID | MONDO:0001688 |
| MeSH | D000081028 |
| DOID | DOID:13329 |
| ICD-10-CM | H46.3 |
| ICD-11 | 1481748859 |
| SNOMED CT | 26125006 |
| UMLS | C0155303 |
| MedGen | 509903 |
| GARD | 0027585 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of optic neuritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › optic nerve disorder › optic neuritis › toxic optic neuropathy
Related subtypes (4): toxic or nutritional optic neuropathy, optic papillitis, retrobulbar neuritis, autoimmune optic neuritis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
| PHASE2/PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04877067 | PHASE3 | COMPLETED | Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation |
| NCT05748561 | PHASE2/PHASE3 | UNKNOWN | Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial. |
| NCT05353413 | Not specified | UNKNOWN | Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy. |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| METHYLPREDNISOLONE HEMISUCCINATE | 4 | 1 |